GeneDx launches prenatal whole genome sequencing test

GeneDx (NASDAQ: WGS) announced the launch of GenomeDx Prenatal, a whole genome sequencing test designed for pregnancies with fetal anomalies identified through ultrasound. The test will be available for clinicians to order in February 2026.

The phenotype-informed, trio-based test aims to provide genomic insights with a rapid turnaround time of less than two weeks when fetal anomalies are detected. GeneDx states the test is intended to help determine whether a pregnancy is affected by a genetic disorder, as opposed to screening tests that identify pregnancies at risk.

The company reports it has performed more than 4,000 prenatal exomes over a decade of experience in prenatal diagnostics. GenomeDx Prenatal builds on this foundation and utilizes GeneDx Infinity, the company's rare disease dataset.

"Families and clinicians facing complex fetal findings need precise, fast, and actionable answers they can trust," said Katherine Stueland, President and CEO of GeneDx. "GenomeDx Prenatal extends our industry-leading diagnostic capabilities into prenatal care, helping identify rare disease at the earliest moment possible."

According to the company, structural anomalies detected on prenatal ultrasound are frequently linked to genetic conditions, with significant fetal structural anomalies identified in up to 4% of pregnancies. The test provides detection across indications including congenital heart disease, skeletal dysplasia, brain and kidney malformations, increased nuchal translucency, and hydrops.

GeneDx will offer free postnatal reanalysis and optional lifetime reanalysis as part of the service. The company states that prenatal genomic sequencing has been shown to influence clinical management in up to 70% of cases in published research.

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• Home Depot expands executive roles, grants $500K in restricted stock
• Alzamend Neuro (ALZN) files for 98.4M share offering by selling stockholders